

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number  
**WO 2004/063193 A1**

- (51) International Patent Classification<sup>7</sup>: **C07D 409/06**, 405/06, 211/70, 401/06, 417/06, C07C 311/08, A61K 31/4436, 31/443, 31/44, 31/444, 31/4439, A61P 25/04, 25/22, 1/04
- (21) International Application Number: PCT/GB2004/000061
- (22) International Filing Date: 13 January 2004 (13.01.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0300104-7 16 January 2003 (16.01.2003) SE
- (71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).
- (71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, Greater London, London W1K 1LN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BROWN, William** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St Laurent, Québec H4S 1Z9 (CA). **GRIFFIN, Andrew** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Québec H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, St. Laurent, Quebec H4S 1Z9 (CA).
- (74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-{ '3-(SULFONYLAMINO) PHENYL' '1-(CYCLYMETHYL) PIPERIDIN-4-YLIDENE' METHYL } BENAZMIDE DERIVATIVES AS DELTA OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN, ANXIETY AND FUNCTIONAL GASTROINTESTINAL DISORDER



(I)

(57) Abstract: Compounds of general formula: (I) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.